Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder

Lawrence Scahill, Karen Bearss, Rena Sarhangian, Christopher J. McDougle, L. Eugene Arnold, Michael G. Aman, James T. McCracken, Elaine Tierney, Scott Gillespie, Valentina Postorino, Benedetto Vitiello

Research output: Contribution to journalArticle

Abstract

Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder. Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study. Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%. Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.

Original languageEnglish (US)
Pages (from-to)125-131
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume27
Issue number2
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Methylphenidate
Pervasive Child Development Disorders
Placebos
Outcome Assessment (Health Care)
Attention Deficit Disorder with Hyperactivity
Checklist
Cross-Over Studies
Clinical Trials

Keywords

  • Autism spectrum disorder
  • Double-blind method
  • Methylphenidate
  • Patient-centered outcomes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Scahill, L., Bearss, K., Sarhangian, R., McDougle, C. J., Arnold, L. E., Aman, M. G., ... Vitiello, B. (2017). Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 27(2), 125-131. DOI: 10.1089/cap.2016.0107

Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. / Scahill, Lawrence; Bearss, Karen; Sarhangian, Rena; McDougle, Christopher J.; Arnold, L. Eugene; Aman, Michael G.; McCracken, James T.; Tierney, Elaine; Gillespie, Scott; Postorino, Valentina; Vitiello, Benedetto.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 27, No. 2, 01.03.2017, p. 125-131.

Research output: Contribution to journalArticle

Scahill, L, Bearss, K, Sarhangian, R, McDougle, CJ, Arnold, LE, Aman, MG, McCracken, JT, Tierney, E, Gillespie, S, Postorino, V & Vitiello, B 2017, 'Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder' Journal of Child and Adolescent Psychopharmacology, vol 27, no. 2, pp. 125-131. DOI: 10.1089/cap.2016.0107

Scahill, Lawrence; Bearss, Karen; Sarhangian, Rena; McDougle, Christopher J.; Arnold, L. Eugene; Aman, Michael G.; McCracken, James T.; Tierney, Elaine; Gillespie, Scott; Postorino, Valentina; Vitiello, Benedetto / Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 27, No. 2, 01.03.2017, p. 125-131.

Research output: Contribution to journalArticle

@article{d723f7c99026455ab172540e3220c3e8,
title = "Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder",
abstract = "Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder. Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study. Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%. Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.",
keywords = "Autism spectrum disorder, Double-blind method, Methylphenidate, Patient-centered outcomes",
author = "Lawrence Scahill and Karen Bearss and Rena Sarhangian and McDougle, {Christopher J.} and Arnold, {L. Eugene} and Aman, {Michael G.} and McCracken, {James T.} and Elaine Tierney and Scott Gillespie and Valentina Postorino and Benedetto Vitiello",
year = "2017",
month = "3",
doi = "10.1089/cap.2016.0107",
volume = "27",
pages = "125--131",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder

AU - Scahill,Lawrence

AU - Bearss,Karen

AU - Sarhangian,Rena

AU - McDougle,Christopher J.

AU - Arnold,L. Eugene

AU - Aman,Michael G.

AU - McCracken,James T.

AU - Tierney,Elaine

AU - Gillespie,Scott

AU - Postorino,Valentina

AU - Vitiello,Benedetto

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder. Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study. Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%. Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.

AB - Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder. Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study. Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%. Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.

KW - Autism spectrum disorder

KW - Double-blind method

KW - Methylphenidate

KW - Patient-centered outcomes

UR - http://www.scopus.com/inward/record.url?scp=85016111808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016111808&partnerID=8YFLogxK

U2 - 10.1089/cap.2016.0107

DO - 10.1089/cap.2016.0107

M3 - Article

VL - 27

SP - 125

EP - 131

JO - Journal of Child and Adolescent Psychopharmacology

T2 - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -